JAK/TYK2

Article

Treat-to-Target has Excellent 10-Year Outcomes in RA

MedPage Today

Most patients with rheumatoid arthritis (RA) whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said.

Dr. John Cush Tweet
@RheumNow
Cryptococcus is rare, but twice as likely with JAK inhibitors. Retrospective TriNetX analysis of RA pts (>30k/grp) starting JAKi vs TNFi; JAKi vs non-TNFi; & TNFi vs non-TNF. Crypto seen in <0.2% in all groups; but signif higher HR for JAKi (HR 2.2 & 2.15) https://t.co/fJeKwDZABL
Dr. John Cush Tweet
@RheumNow
No difference in MACE risk betw TNFi vs JAKi in 6174 RA pts. Korean claims data compared TNFi (n 5,152) vs JAKi (n 1,022) initiators. MACE risk was 4.1 & 3.6/1000PYs w/ TNFi vs JAKi, respectively. MACE risk did not differ significantly between JAKi and TNFi (adj HR 0.636; 0.283, https://t.co/035WSUQAhJ
Dr. John Cush Tweet
@RheumNow
Don't Hold the Biologic or JAK with COVID-19 Vaccination A randomized clinical trial in inflammatory arthritis arthritis shows that temporarily holding biologic or Janus kinase (JAK) inhibitor therapy at the time of COVID-19 vaccination is not warranted. https://t.co/O9iJHEfp42
Article

Treatment Landscape for Dermatomyositis Is Evolving

MedPage Today

After years of inactivity, therapeutic development for dermatomyositis has begun to move forward with several new therapies and therapeutic strategies.

"This is a very exciting time for the field because we're finally going to get some new treatments, and I think it will be helpful in

Dr. John Cush Tweet
@RheumNow
Don't Hold the Biologic or JAK with COVID-19 Vaccination A randomized clinical trial in inflammatory arthritis arthritis shows that temporarily holding biologic or Janus kinase (JAK) inhibitor therapy at the time of COVID-19 vaccination is not warranted. https://t.co/moQIE09lvi
Dr. John Cush Tweet
@RheumNow
Steroids are easy to start and hard to stop. Hold the MTX, but not the biologic or JAK. And what’s the latest on avacopan? This week, Dr. Jack Cush reviews the rheumatology news you don’t want to miss: from new approvals and promising trial results to sobering Sjögren’s data, https://t.co/UC4RdHMaFS
Article

Don’t Hold the JAK (10.9.2026)

Jack Cush, MD

On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients. 

Dr. John Cush Tweet
@RheumNow
DERM on RheumNow PODCAST (September 2026) The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors. https://t.co/QYX9G5UFg5
Dr. John Cush Tweet
@RheumNow
52 VEXAS pts Rx w/ IL‐1i, IL‐6i, or JAKi therapy judged as compl Resp (CR), partial (PR), Failure (TF). @ 6mos: 3/19 IL‐6i had CR, 4/19 PR, 7/19 TF. JAKi had 2/17 CR, 3/17 PR, 6/17 TF. No CR w/ IL‐1i or TNFαi, only 1/5 IL‐1i patients experienced PR. Only IL‐6i & JAKi had https://t.co/wqogmfeAru
Dr. John Cush Tweet
@RheumNow
True or False: The TriNetX retrospective study found that JAK inhibitors significantly increased VTE risk in rheumatoid arthritis patients undergoing hip or knee replacement compared to TNF inhibitors. Check your knowledge in the latest RheumIQ quiz at https://t.co/LHFv1P6XZe.

Therapeutic Updates

A JAKi CHAT: Shared Decision-Making in RA

AbbVie October
Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.
Read Post

Recent Blogs

JAKi for PMR: Safe, or a Concern for Older Adults?

David Liew, FRACP
Dr. David Liew
JAK inhibitors obviously have dominated a lot of the discussion in our therapeutic landscape over the last couple of years. What about their use in polymyalgia rheumatica? Let's consider.
Read Post

Infections Rheums Should Worry About

Cassandra Calabrese, DO
TB.EMimage.CDC_.jpg
With the increasing development and use of new biologics and oral targeted therapies to treat RA and other immune mediated inflammatory diseases, an awareness of infection risk and prevention has become of increasing interest as well. While our patients may be susceptible to many different types of infections depending on immunosuppressive regimen, age and co-morbidities, I’ll highlight a few of the “usual suspects”.
Read Post

Hard Conversations: DMARDs and Malignancy

Michael Putman, MD, MSCI
Risk Option Decision
Cancer is the most difficult DMARD risk to discuss with patients. Few warnings could scare people away from a drug faster than the words “may increase risk of cancer,” yet the risks (even when substantiated) have all been low and may be counterbalanced by the benefits of disease control.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • PsA Topic Podcast compilation
  • EULAR 2026 Daily Podcast Day 4c
  • EULAR 2026 Daily Podcast Day 4a

Topic Videos
×